Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New feature: Automatically detect candlestick patterns on any chart

Tango Therapeutics, Inc.

Contributing Author

Recent Articles by Tango Therapeutics, Inc.

Aug-11	Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights TNGX GlobeNewswire
Aug-06	Tango Therapeutics Announces Executive Chair Transition TNGX TNGX -6.66% GlobeNewswire
Aug-06	Tango Therapeutics Announces Executive Chair Transition TNGX TNGX -6.66% GlobeNewswire
Jun-22	Tango Therapeutics Appoints Robert Azelby to Board of Directors TNGX GlobeNewswire
Jun-09	Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering TNGX -9.13% GlobeNewswire
Jun-08	Tango Therapeutics Announces Proposed $500 Million Public Offering TNGX +52.97% GlobeNewswire
Jun-08	Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer TNGX +52.97% GlobeNewswire
Jun-05	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TNGX -8.71% GlobeNewswire
May-13	Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights TNGX +8.55% GlobeNewswire
Oct-06	Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 TNGX GlobeNewswire
Aug-26	Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference TNGX GlobeNewswire
Aug-05	Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights TNGX GlobeNewswire
Jul-22	Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 TNGX GlobeNewswire
Jun-27	Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer TNGX GlobeNewswire
May-27	Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference TNGX +11.41% GlobeNewswire
May-21	Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors TNGX -8.70% GlobeNewswire
May-12	Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights TNGX +14.91% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)